Kensey Nash Provides 4th Quarter Fiscal 2008 and Fiscal Year 200...(o support the exciting opportunities tha...),Health

Date:6/23/2008

o support the exciting opportunities that we believe will have substantial impact on the long-term growth of our Company. We will place significant focus on our cartilage repair product this coming year, where efforts will be dedicated to pre-clinical and clinical programs to further this product toward regulatory approval. In addition, we will perform the development of the next generation ThromCat(TM) and SafeCross(TM) products pursuant to our recent agreement with Spectranetics, under which we will earn milestones for FDA approval of such next generation endovascular products. These products will also provide additional future opportunities to expand both revenue and earnings for our Company.

In closing, we expect that our operating margins will continue to substantially improve and exceed 30% in fiscal year 2009. As a result of our anticipated revenue growth coupled with the expanding operating margins, we believe earnings per share for fiscal 2009 will increase between 65% and 70% over our forecasted 2008 results, to a range of $1.57 to $1.65 per share. We are very excited about our prospects in fiscal year 2009 and beyond."

Share Buyback

The Company is also announcing that its board of directors has expanded its existing $25.0 million stock repurchase program in order to provide the Company with more flexibility to buy its own shares. The new program allows the Company to repurchase up to an additional $10.0 million of its issued and outstanding shares of Common Stock and has no expiration. The Company intends to finance the repurchases using its available cash, which it forecasts at approximately $58.0 to $60.0 million by June 30, 2008. Kensey Nash Corporation plans to repurchase its shares for cash, from time to time in the open market, through block trades or otherwise. The repurchase program does not require the Company to purchase any specific dollar value or number of shares. Any purchases under the program will depend on market cond
'/>"/>

SOURCE Kensey Nash Corporation Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine news :

1. Kensey Nash Corporation Announces its First Quarter 2008 Earnings Release Date and Teleconference
2. Kensey Nash Announces $25 Million Stock Repurchase Program
3. Kensey Nash Reports Acceleration of Stock Awards Triggered by Shareholder Acquisition of Greater Than 20% of Outstanding Shares
4. Kensey Nash Reports First Quarter Fiscal Year 2008 Results
5. Kensey Nash Announces Exclusive License of Optical Guidance Patent to Enhance Chronic Total Occlusion Platform
6. Kensey Nash to Present at the 19th Annual Piper Jaffray Health Care Conference
7. Kensey Nash Corporation Announces Its Second Quarter 2008 Earnings Release Date and Teleconference
8. Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million
9. Kensey Nash to Participate in the Sidoti Twelfth Annual New York Emerging Growth Institutional Investor Forum Conference
10. Kensey Nash Reports Third Quarter Record Revenue and Sales
11. Kensey Nash to Present at the Bank of America 2008 Health Care Conference